Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses
Human respiratory syncytial virus (HRSV), human metapneumovirus (HMPV), and human parainfluenza viruses (HPIVs) are leading causes of respiratory disease in young children, the elderly, and individuals of all ages with immunosuppression. Vaccination strategies against these pneumoviruses and paramyx...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/6/1023 |
| _version_ | 1827691140296474624 |
|---|---|
| author | Charles J. Russell Julia L. Hurwitz |
| author_facet | Charles J. Russell Julia L. Hurwitz |
| author_sort | Charles J. Russell |
| collection | DOAJ |
| description | Human respiratory syncytial virus (HRSV), human metapneumovirus (HMPV), and human parainfluenza viruses (HPIVs) are leading causes of respiratory disease in young children, the elderly, and individuals of all ages with immunosuppression. Vaccination strategies against these pneumoviruses and paramyxoviruses are vast in number, yet no licensed vaccines are available. Here, we review development of Sendai virus (SeV), a versatile pediatric vaccine that can (a) serve as a Jennerian vaccine against HPIV1, (b) serve as a recombinant vaccine against HRSV, HPIV2, HPIV3, and HMPV, (c) accommodate foreign genes for viral glycoproteins in multiple intergenic positions, (d) induce durable, mucosal, B-cell, and T-cell immune responses without enhanced immunopathology, (e) protect cotton rats, African green monkeys, and chimpanzees from infection, and (f) be formulated into a vaccine cocktail. Clinical phase I safety trials of SeV have been completed in adults and 3–6-year-old children. Clinical testing of SeVRSV, an HRSV fusion (F) glycoprotein gene recombinant, has also been completed in adults. Positive results from these studies, and collaborative efforts with the National Institutes of Health and the Serum Institute of India assist advanced development of SeV-based vaccines. Prospects are now good for vaccine successes in infants and consequent protection against serious viral disease. |
| first_indexed | 2024-03-10T10:54:43Z |
| format | Article |
| id | doaj.art-87304e030ff64cd0bc2a23cb91ae52c5 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T10:54:43Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-87304e030ff64cd0bc2a23cb91ae52c52023-11-21T21:58:01ZengMDPI AGViruses1999-49152021-05-01136102310.3390/v13061023Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory VirusesCharles J. Russell0Julia L. Hurwitz1Department of Infectious Diseases, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USADepartment of Infectious Diseases, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USAHuman respiratory syncytial virus (HRSV), human metapneumovirus (HMPV), and human parainfluenza viruses (HPIVs) are leading causes of respiratory disease in young children, the elderly, and individuals of all ages with immunosuppression. Vaccination strategies against these pneumoviruses and paramyxoviruses are vast in number, yet no licensed vaccines are available. Here, we review development of Sendai virus (SeV), a versatile pediatric vaccine that can (a) serve as a Jennerian vaccine against HPIV1, (b) serve as a recombinant vaccine against HRSV, HPIV2, HPIV3, and HMPV, (c) accommodate foreign genes for viral glycoproteins in multiple intergenic positions, (d) induce durable, mucosal, B-cell, and T-cell immune responses without enhanced immunopathology, (e) protect cotton rats, African green monkeys, and chimpanzees from infection, and (f) be formulated into a vaccine cocktail. Clinical phase I safety trials of SeV have been completed in adults and 3–6-year-old children. Clinical testing of SeVRSV, an HRSV fusion (F) glycoprotein gene recombinant, has also been completed in adults. Positive results from these studies, and collaborative efforts with the National Institutes of Health and the Serum Institute of India assist advanced development of SeV-based vaccines. Prospects are now good for vaccine successes in infants and consequent protection against serious viral disease.https://www.mdpi.com/1999-4915/13/6/1023vaccine vectorparainfluenza virusparamyxoviruspneumovirusHRSVenvelope glycoprotein |
| spellingShingle | Charles J. Russell Julia L. Hurwitz Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses Viruses vaccine vector parainfluenza virus paramyxovirus pneumovirus HRSV envelope glycoprotein |
| title | Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses |
| title_full | Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses |
| title_fullStr | Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses |
| title_full_unstemmed | Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses |
| title_short | Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses |
| title_sort | sendai virus vectored vaccines that express envelope glycoproteins of respiratory viruses |
| topic | vaccine vector parainfluenza virus paramyxovirus pneumovirus HRSV envelope glycoprotein |
| url | https://www.mdpi.com/1999-4915/13/6/1023 |
| work_keys_str_mv | AT charlesjrussell sendaivirusvectoredvaccinesthatexpressenvelopeglycoproteinsofrespiratoryviruses AT julialhurwitz sendaivirusvectoredvaccinesthatexpressenvelopeglycoproteinsofrespiratoryviruses |